227 related articles for article (PubMed ID: 26864324)
1. Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2.
Scheuer W; Thomas M; Hanke P; Sam J; Osl F; Weininger D; Baehner M; Seeber S; Kettenberger H; Schanzer J; Brinkmann U; Weidner KM; Regula J; Klein C
MAbs; 2016; 8(3):562-73. PubMed ID: 26864324
[TBL] [Abstract][Full Text] [Related]
2. Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy.
Kienast Y; Klein C; Scheuer W; Raemsch R; Lorenzon E; Bernicke D; Herting F; Yu S; The HH; Martarello L; Gassner C; Stubenrauch KG; Munro K; Augustin HG; Thomas M
Clin Cancer Res; 2013 Dec; 19(24):6730-40. PubMed ID: 24097868
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model.
Mueller T; Freystein J; Lucas H; Schmoll HJ
Molecules; 2019 Aug; 24(16):. PubMed ID: 31394786
[TBL] [Abstract][Full Text] [Related]
4. Effect of Ang-2-VEGF-A Bispecific Antibody in Renal Cell Carcinoma.
Bessho H; Wong B; Huang D; Tan J; Ong CK; Iwamura M; Hart S; Dangl M; Thomas M; Teh BT
Cancer Invest; 2015; 33(8):378-86. PubMed ID: 26115098
[TBL] [Abstract][Full Text] [Related]
5. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
6. A bispecific antibody effectively inhibits tumor growth and metastasis by simultaneous blocking vascular endothelial growth factor A and osteopontin.
Kou G; Shi J; Chen L; Zhang D; Hou S; Zhao L; Fang C; Zheng L; Zhang X; Liang P; Zhang X; Li B; Guo Y
Cancer Lett; 2010 Dec; 299(2):130-6. PubMed ID: 20826049
[TBL] [Abstract][Full Text] [Related]
7. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.
Kloepper J; Riedemann L; Amoozgar Z; Seano G; Susek K; Yu V; Dalvie N; Amelung RL; Datta M; Song JW; Askoxylakis V; Taylor JW; Lu-Emerson C; Batista A; Kirkpatrick ND; Jung K; Snuderl M; Muzikansky A; Stubenrauch KG; Krieter O; Wakimoto H; Xu L; Munn LL; Duda DG; Fukumura D; Batchelor TT; Jain RK
Proc Natl Acad Sci U S A; 2016 Apr; 113(16):4476-81. PubMed ID: 27044098
[TBL] [Abstract][Full Text] [Related]
8. A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors.
Thomas M; Kienast Y; Scheuer W; Bähner M; Kaluza K; Gassner C; Herting F; Brinkmann U; Seeber S; Kavlie A; Welschof M; Ries S; Weidner KM; Regula JT; Klein C
PLoS One; 2013; 8(2):e54923. PubMed ID: 23405099
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis.
Lee D; Kim D; Choi YB; Kang K; Sung ES; Ahn JH; Goo J; Yeom DH; Jang HS; Moon KD; Lee SH; You WK
MAbs; 2016 Jul; 8(5):892-904. PubMed ID: 27049350
[TBL] [Abstract][Full Text] [Related]
10. Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.
Baker LCJ; Boult JKR; Thomas M; Koehler A; Nayak T; Tessier J; Ooi CH; Birzele F; Belousov A; Zajac M; Horn C; LeFave C; Robinson SP
Br J Cancer; 2016 Sep; 115(6):691-702. PubMed ID: 27529514
[TBL] [Abstract][Full Text] [Related]
11. Nanocell targeting using engineered bispecific antibodies.
Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.
Peterson TE; Kirkpatrick ND; Huang Y; Farrar CT; Marijt KA; Kloepper J; Datta M; Amoozgar Z; Seano G; Jung K; Kamoun WS; Vardam T; Snuderl M; Goveia J; Chatterjee S; Batista A; Muzikansky A; Leow CC; Xu L; Batchelor TT; Duda DG; Fukumura D; Jain RK
Proc Natl Acad Sci U S A; 2016 Apr; 113(16):4470-5. PubMed ID: 27044097
[TBL] [Abstract][Full Text] [Related]
13. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.
Regula JT; Lundh von Leithner P; Foxton R; Barathi VA; Cheung CM; Bo Tun SB; Wey YS; Iwata D; Dostalek M; Moelleken J; Stubenrauch KG; Nogoceke E; Widmer G; Strassburger P; Koss MJ; Klein C; Shima DT; Hartmann G
EMBO Mol Med; 2016 Nov; 8(11):1265-1288. PubMed ID: 27742718
[TBL] [Abstract][Full Text] [Related]
14. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
Zhang L; Yang N; Park JW; Katsaros D; Fracchioli S; Cao G; O'Brien-Jenkins A; Randall TC; Rubin SC; Coukos G
Cancer Res; 2003 Jun; 63(12):3403-12. PubMed ID: 12810677
[TBL] [Abstract][Full Text] [Related]
15. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model.
Whitehurst B; Flister MJ; Bagaitkar J; Volk L; Bivens CM; Pickett B; Castro-Rivera E; Brekken RA; Gerard RD; Ran S
Int J Cancer; 2007 Nov; 121(10):2181-91. PubMed ID: 17597103
[TBL] [Abstract][Full Text] [Related]
16. The bispecific antibody HB-32, blockade of both VEGF and DLL4 shows potent anti-angiogenic activity in vitro and anti-tumor activity in breast cancer xenograft models.
Zhou R; Wang S; Wen H; Wang M; Wu M
Exp Cell Res; 2019 Jul; 380(2):141-148. PubMed ID: 31034805
[TBL] [Abstract][Full Text] [Related]
17. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
18. A dual-targeting PDGFRbeta/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo.
Mabry R; Gilbertson DG; Frank A; Vu T; Ardourel D; Ostrander C; Stevens B; Julien S; Franke S; Meengs B; Brody J; Presnell S; Hamacher NB; Lantry M; Wolf A; Bukowski T; Rosler R; Yen C; Anderson-Haley M; Brasel K; Pan Q; Franklin H; Thompson P; Dodds M; Underwood S; Peterson S; Sivakumar PV; Snavely M
MAbs; 2010; 2(1):20-34. PubMed ID: 20065654
[TBL] [Abstract][Full Text] [Related]
19. Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab.
Khan M; Aziz AA; Shafi NA; Abbas T; Khanani AM
Cells; 2020 Aug; 9(8):. PubMed ID: 32785136
[TBL] [Abstract][Full Text] [Related]
20. Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis.
Bachelier R; Confavreux CB; Peyruchaud O; Croset M; Goehrig D; van der Pluijm G; Clézardin P
Int J Cancer; 2014 Sep; 135(6):1319-29. PubMed ID: 24615579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
